Relay Therapeutics Q1 net loss $62M ($0.57/shr); cash $898M; RLY-2608 combo arm initiated

Relay Therapeutics, Inc.

2023-Q1 EPS reported -$0.57 revenue$419,000

Net loss of $62.0M ($0.57/shr) vs $42.2M ($0.47) in Q1 2021; R&D expenses rose to $51.7M.
Cash, equivalents and investments $898M (down from $958M at Dec 31, 2021); sufficient into 2025.
Initiated fulvestrant combination arm of RLY-2608 (pan-mutant PI3Kα inhibitor) dose escalation; initial data expected H1 2023.
RLY-4008 (FGFR2 inhibitor) received FDA orphan drug designation for cholangiocarcinoma; expansion cohorts enrolling.
Virtual analyst/investor event on June 27, 2022 to announce new target.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.